Psyence Biomedical logo

Psyence Biomedical(NASDAQ) PBM

Market Cap$18.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 Year-79%
1 Month+3%
$4.96
-3.13%
-0.16Today
After hours$4.93-$0.03 (-0.61%)
Psyence Biomedical last closing stock price
MetricPriceDate
Last closeUSD 4.972026-10-09
Psyence Biomedical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.68%USD 5.162026-10-02
1 month+2.69%USD 4.842026-09-09
3 month+67.34%USD 2.972026-07-10
Year to date+5.55%USD 4.712025-12-31
1 year-78.51%USD 23.132025-10-09
Since inception-99.99%USD 36,985.882021-12-10

Psyence Biomedical Financials at a Glance

Market Cap

$18.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$26.25M

EPS (TTM)

$0.00

P/E Ratio

-31.48

Dividend

$0.00

Beta (Volatility)

1.84 (High)

Price

$4.96

Volume

23,963.085

Open

$5.21

Previous Close

$4.97

Daily Range

$4.93 - $5.21

52-Week Range

$1.92 - $23.38

Estimated Earnings Date

Sep 28, 2026

PBM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Psyence Biomedical

Psyence Biomedical Ltd. is focused on advancing psychedelic medicines derived from botanical psilocybin. The company is exploring natural psilocybin as a potential therapy for adjustment disorder in patients with incurable cancer undergoing palliative care.

Products and Services
  • PEX010: A leading investigational drug in Phase IIb clinical study
  • Psilocybin-assisted psychotherapy for adjustment disorder
  • Strategic alliance with PsyLabs for Ibogaine manufacturing
Growth Outlook
  • Partnership with iNGENu for clinical trials enhances research capabilities
  • Increasing interest in psychedelic therapies supports market potential
  • Focus on palliative care aligns with growing healthcare needs
Financial Highlights
  • Recent quarterly net income of -$753,254 reflects ongoing investment in R&D
  • Cash and short-term investments of $7.2 million provide operational flexibility
  • Current ratio of 14.62 indicates strong liquidity position
Psyence Biomedical Ltd. operates in the biotechnology sector, emphasizing the development of innovative therapies for mental health conditions. The company's flagship product, PEX010, is designed to address anxiety and depression, particularly in patients facing terminal illnesses. The strategic partnerships and clinical trials signify a commitment to advancing research in this emerging field. Financially, while the company is currently operating at a loss, the substantial cash reserves and high current ratio suggest a robust capacity to fund ongoing research and development initiatives. The growing acceptance of psychedelic therapies in mainstream medicine presents a significant opportunity for future growth.
AI Generated • Sep 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

12

CEO

Neil Maresky, MD

Website

psyence.com

Headquarters

Toronto, ON M5H 2K1, CA

PBM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-58.62%

Return on Capital

-36.81%

Return on Assets

-39.48%

Earnings Yield

-3.18%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$18.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.81M

Volume

23.96K

Avg. Volume

94.22K

Financials (TTM)

Gross Profit

-$2.35K

Operating Income

-$3.47M

EBITDA

-$2.11M

Operating Cash Flow

-CA$1.05M

Capital Expenditure

-CA$7.80

Free Cash Flow

-CA$1.05M

Cash & ST Invst.

$7.20M

Total Debt

$0.00

Psyence Biomedical Performance Analysis

Psyence Biomedical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20242024-03-31USD 0N/A
20252025-03-31USD 0N/A
20262026-03-31USD 0N/A
Psyence Biomedical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-09-30N/A
Q32023-12-31N/A
Q22024-09-30N/A
Q22025-09-30N/A
Psyence Biomedical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.53-2.6%
20242024-03-31USD -49.06N/A
20252025-03-31USD 1.40N/A
20262026-03-31USD -12.56N/A
Psyence Biomedical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-09-30-979.5%
Q32023-12-31-2097.1%
Q22024-09-30N/A
Q22025-09-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$1.33K

N/A

Gross Margin

0.00%

N/A

Market Cap

$18.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.58M

N/A

Employees

12

N/A

Net Income

-$753.25K

-1098.6%

EBITDA

-$749.17K

-799.9%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$7.20M

+73325.6%

Total Debt

$0.00

-100.0%

Accounts Receivable

$174.19K

+159.3%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-39.48%

N/A

Return on Invested Capital

-36.81%

N/A

Free Cash Flow

-$665.00

+99.2%

Operating Cash Flow

-$662.00

+99.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GTBPGT Biopharma, Inc.
$6.68+12.08%
DRMADermata Therapeutics, Inc.
$1.02-4.67%
REVBRevelation Biosciences, Inc.
$0.76-1.81%
NKGNNKGen Biotech, Inc. Common Stock
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About PBM

What is the current price of Psyence Biomedical?

Psyence Biomedical is trading at $4.97 per share.

What is the 52-week range for Psyence Biomedical?

Over the past 52 weeks, Psyence Biomedical has traded between $1.92 and $23.38.

How much debt does Psyence Biomedical have?

As of the most recent reporting period, Psyence Biomedical reported total debt of $0.00.

How much cash does Psyence Biomedical have on hand?

Psyence Biomedical reported $7.20M in cash and cash equivalents in its most recent financial results.

What is Psyence Biomedical’s dividend yield?

Psyence Biomedical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services